NL-OMON39139已完成不适用
A phase 1 multicenter, open label, dose-escalation study of oral LEE011 in patients with advanced solid tumors or lymphomas. - A phase I study with LEE011, a CDK4/6 inhibitor
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Patients with a histologically or cytologically confirmed diagnosis of a solid tumor or lymphoma for which no further effective standard treatment is available
- •1) dose escalation phase: pRb-positive tumor tissue (immunohistochemical analysis)
- •2) dose expansion phase: tumors known to have aberrant activation of the D-cyclin-CDK4/6-INK4a-pRb pathway or whose tumors can be shown to harbor such an abnormality identified by IHC, by mutation analysis or by FISH. Patients with MCL, liposarcoma, HPVnegative HNSCC, melanoma, ER+ breast cancer and neuroblastoma are permitted to be enrolled in the study without documented pRb status.
- •A representative tumor specimen must be available for molecular testing. An archival tumor sample may be submitted; however, if one is not available, a newly obtained tumor biopsy specimen must be submitted instead.
- •- WHO performance status 0 or 1.
- •- Required baseline laboratory values:
- •o Absolute Neutrophil Count *1.5 x 109/L
- •o Hemoglobin * 9 g/dl <= 5.58 mmol/l
- •o Platelets * 100x109/L
- •o AST/SGOT and ALT/SGPT* 3 x Upper Limit of Normal (ULN) or * 5.0 x ULN if liver metastases are present
- •o Serum bilirubin * 1.5 x ULN
- •o Serum creatinine * 1.5 x ULN or 24-hour clearance * 50 ml/min.
- •o Potassium, magnesium and calcium within clinical relevant limits
- •- A sufficient interval must have elapsed between the last dose of prior anti-cancer therapy (including cytotoxic and biological therapies and major surgery) and enrollment in this study, to allow the effects of prior therapy to have abated.
- •- Patients enrolled in the dose expansion phase must have at least one measurable lesion as defined by RECIST criteria for solid tumors or measurable nodal disease at baseline as defined by Cheson criteria for lymphoma.
- •- A negative serum pregnancy test * 72 hours before starting study treatment
排除标准
- •- Patients with primary CNS tumors or brain metastases. However, if over a minimum of 3 months the disease is stable (confirmed by MRI) and if the patient remains asymptomatic, then the patient may be enrolled. Such patients must have no need for treatment with steroids or anti-epileptic medications.
- •-Impairment of gastro-intestinal (GI) function or GI disease that may significantly alter the absorption of LEE011 and clinically significant gastroparesis, nausea, vomiting, or diarrhea of CTCAE grade > 1
- •- Autologous stem cell transplant within 3 months before the first dose of LEE011 or prior allogeneic stem cell transplant at any time
- •- Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
- •1) Left ventricular ejection fraction (LVEF) <45%
- •2) Complete left bundle branch block
- •3) Obligate use of a cardiac pacemaker or implantable cardioverter defibrillator
- •4) Congenital long QT syndrome or family history of unexpected sudden cardiac death
- •5) History or presence of ventricular tachyarrhythmia
- •6) Presence of unstable atrial fibrillation
- •7) Clinically significant resting bradycardia
- •8) QTcF >450 ms for males and >470 ms for females on screening ECG
- •9) Right bundle branch block and left anterior hemiblock (bifascicular block)
- •10) Acute MI or angina pectoris * 3 months prior to starting study drug
- •11) Other clinically significant heart disease
- •- The use of agents that are known to cause QTc prolongation
- •- Treatment with agents including vitamins, supplements, and herbal supplements that are either (i) metabolized solely through CYP3A4/5, CYP1A2 or BSEP and have a narrow therapeutic window or (ii) are strong inhibitors of CYP3A4/5, CYP1A2 or BSEP
- •- Concurrent severe and/or uncontrolled concurrent medical conditions e.g., uncontrolled hypertension and/or diabetes mellitus, clinically significant pulmonary disease, clinically significant neurological disorder, active or uncontrolled infection.
- •- Pregnant or lactating women.
- •- Women of childbearing potential and men with reproductive potential unwilling to use adequate contraception whilst on study therapy and for 3 months thereafter
研究者
相似试验
已完成
不适用
A phase I, open label, multicenter, dose-escalation study of oral HDM201 in adult patients with advanced solid and hematological tumors characterized by wild-type TP53Solid and hematologic tumors1002432410027655NL-OMON46915ovartis24
已完成
不适用
A multicenter, open label, phase 1 dose escalation study to evaluate the pharmacokinetics, safety, and tolerability of INC280 tablet formulation with food in patients with cMET dysregulated advanced solid tumorsNL-OMON43009ovartis3
招募中
1 期
A Study of AZD0486 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin LymphomaB-Cell Non-Hodgkin LymphomaJPRN-jRCT2041230077Misaki Masako9
已完成
不适用
A phase I, multicenter, open-label dose escalation and expansion study of LOP628, administered intravenously in adult patients with cKit-positive tumors and acute myeloid leukemiaSmall Cell Lung cancerAcute Myeloide Leukemia10027655GISTNL-OMON42287ovartis15
已完成
不适用
A phase I, multicenter, open-label dose escalation study of LDK378, administered orally in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase(ALK)Tumors with genetic abnormality in ALK10027655NL-OMON36240ovartis4